Member Spotlight: Sofinnova Investments


This post is by Savanna Maloney from National Venture Capital Association – NVCA


For this deep dive, we spoke to Maha Katabi, PhD, CFA, General Partner at Sofinnova Investments.
Maha Katabi, PhD, CFA, General Partner at Sofinnova Investments
Tell us about your firm.  What makes it different: Sofinnova Investments is a healthcare investment firm committed to funding innovative products that aspire to meaningfully impact the lives of patients. We actively partner with entrepreneurs across all stages of company formation. Our team is comprised of experienced investors and drug developers with extensive scientific expertise, vast industry knowledge, and a track record of helping companies advance drug development and navigate the regulatory process to potential FDA approval.   Our general partners have an average of 23 years of biotech investing expertise, and our executive partners have on average 25 years of drug development experience. We leverage our team’s deep operational experience to enhance likelihood of success of bringing new therapies to market.  As of 12/31/2023 Sofinnova has $3.7B in assets under management including committed capital, we’re looking to fund products that we believe can be either first in class or best in class drugs approved for patients.  What defines your portfolio? Our core investment strategy is targeting companies developing innovative products in areas of high unmet patient need, for a uniform patient population. We work closely with management teams to establish a clinical development plan that aligns with regulatory standards and follow a clearly defined regulatory path.    Sofinnova is a therapeutic-agnostic firm, which means we invest across a large number of therapeutic areas with (Read more…)